Two small-cap plays with potential heading into earnings this week. Both companies have had significant recent developments since their last 1Q financial reports, so the forward-looking management commentary may be more important than the actual EPS number. **$BESS — Bimergen …
Talk about your daily plays, ideas and strategies that do not warrant an actual post. This is the place to request buy/sell advice from the community. Remember to keep it civil. Trade responsibly.
[removed]
[removed]
Last time I posted the five-week results of 23 unusual-volume names we rejected. Fifteen were down, eight were up, and the three biggest moves against us were the most useful because they forced us to recheck the original reasons for …
[removed]
SAMSUNG: [https://www.reuters.com/world/asia-pacific/netlist-samsung-settle-patent-disputes-new-five-year-memory-deal-2026-08-05/](https://www.reuters.com/world/asia-pacific/netlist-samsung-settle-patent-disputes-new-five-year-memory-deal-2026-08-05/) [https://www.sec.gov/ix?doc=/Archives/edgar/data/1282631/000110465926090641/tm2622153d1\_8k.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1282631/000110465926090641/tm2622153d1_8k.htm) 5-year Global settlement and license signed August 5th: \- Samsung pays **$239mil** upfront gross (before fees, after fees \~$200mil) \- Quarterly royalties of up to **$32.9mil** gross (after fees \~$27.5mil/qr) \- Netlist may purchase up to **$300mil/year** …
CEO Dennis Calvert just accepted stock instead of cash for salary and expenses at these levels. More importantly, those shares are locked until BioLargo reaches **$40M in consolidated revenue** or a **$300M market cap** — roughly **5x current annual revenue** …